Serum Soluble CD163 as a Marker of Activity in MS Patients | ||||
| The Medical Journal of Cairo University | ||||
| Volume 90, Issue 6, June 2022, Page 1039-1045 PDF (464.31 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2022.257370 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| MARWA R. EL NAJJAR, M.D.; MONA M. RAFIK, M.D.; DINA A. SOLIMAN, M.D.; EMAN A.M. HASSAN, M.Sc.; ALAA M. ABOU STEIT, M.D. | ||||
| The Department of Clinical Pathology, Faculty of Medicine, Ain Shams University | ||||
| Abstract | ||||
| Abstract Background: Multiple sclerosis (MS) is a chronic autoim-mune disease that affects the central nervous system. Microglia and macrophages have a substantial role in myelin and axonal degeneration by causing neuro-inflammatory damage. Soluble CD 163 one of the myeloid linage biomarkers, showed a better correlation with monocyte count in the CSF of MS patients. Aim of Study: In the current case control observational study, we aimed to assess serum level of sCD163 as an immunological non-invasive marker for MS activity. Patients and Methods: Sixty relapsing remitting multiple sclerosis (RRMS) patients were included and divided into 2 groups based on disease activity. Twenty-eight matched healthy controls were included and all subjects' serum levels of sCD163 were measured using ELISA. Results: This study demonstrated a highly significant-difference between the whole patients compared to controls with a concomitantno statistically significant difference between the patients' groups. Conclusion: This study emphasized the relevance of serum level of sCD 163 as a non-invasive immunological biomarker in the diagnostic panel of MS reflecting the inflammatory process rather than the activity status of the patients. | ||||
| Keywords | ||||
| Multiple sclerosis; sCD163; RRMS | ||||
|
Statistics Article View: 205 PDF Download: 209 |
||||
